Although research indicates that older adults hospitalized with acute decompensated heart failure (HF) have high rates of poor quality of life, delayed recovery, physical frailty, and frequent rehospitalization, well-established...
Read More
Earlier detection of primary ovarian tumor could extend survival in some patients When complete...
Read MoreIn the phase 2 NANT2011-01 trial, levels of circulating tumor DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time. Neuroblastoma is the most common extracranial...
Read MoreMirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial. Mirvetuximab soravtansine (MIRV) is...
Read MoreFirst results from the phase 3 PEACE-1 trial show that adding abiraterone to androgen deprivation therapy (ADT) plus docetaxel significantly improves progression-free survival in patients who present with de novo metastatic...
Read MoreFirst results of the phase 3 RELATIVITY-047 trial validate the efficacy of dual checkpoint blockade demonstrated with the LAG-3 inhibitor relatlimab and nivolumab in patients with advanced melanoma. Lymphocyte-activation gene 3...
Read MoreAn exploratory post-hoc pooled analysis of three phase 3 trials with atezolizumab in patients with stage IV non-small cell lung cancer (NSCLC) – IMpower130, IMpower132, and IMpower150 – shows longer overall survival for patients...
Read MoreAnalysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment. Gene signatures have proven successful in...
Read MorePatritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a monoclonal antibody to HER3 attached to a topoisomerase I, demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily...
Read MoreAfter initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma. In the phase 3 CheckMate 067...
Read MoreFirst-line treatment of patients with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for...
Read MoreFirst results of the phase 3 KEYNOTE 564 trial show that adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell renal cell cancer (RCC). Nephrectomy...
Read MoreResults of the randomized, phase 3 OUTBACK trial do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer. At 5 years, both overall and progression-free survival were...
Read MoreA first interim analysis of the OlympiA trial demonstrates significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant...
Read MoreAddition of the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit in patients with ER-positive, HER2-negative, locally advanced/metastatic breast cancer, according to the primary analysis of the...
Read MoreFirst results of the randomized, phase 3 CheckMate 648 study demonstrate superior overall survival of first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone. Standard...
Read MoreA 2-year update of the CheckMate 9LA trial shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung...
Read MoreAddition of 177Lu-PSMA-617 therapy to standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival, according to results from the randomized, phase 3 VISION trial....
Read MoreRBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the antitumor immunity, is well tolerated, and demonstrated proof of mechanism in a first-in-human trial. Targeting cytosolic nucleic...
Read MoreFirst results of the GAIN/iCAT2 Consortium trial show the importance of molecular profiling of solid tumors in young patients. Next generation sequencing (NGS) assays are now a standard part of clinical care for many adult solid...
Read More
